A quick history of the tech behind J&J, AstraZeneca’s COVID-19 vaccines

Adenovirus image from Wikipedia

Regulatory authorities in the U.S. and Europe have either paused or constrained the use of COVID-19 vaccines from AstraZeneca (LON:AZN) and Johnson & Johnson (NYSE:JNJ), causing some to wonder why the adenoviral-vector vaccines have been potentially linked to similar blood clotting events.

Researchers have observed blood clotting events associated with adenoviral vectors since the late-1990s in early experiments with the platform. But the safety of the platform has improved as genetic engineering has advanced.

Get the full story from our sister site, Drug Discovery & Development.

Read more
  • 0